Skip to content
Tablet Allopathic

Renib 40 mg tablet

Generic: Regorafenib

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength40 mg
PackBox of 30: 16300.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Regorafenib 40 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Renib, box of 30 (this medicine)543.33 taka per tablet
Regora, box of 10700.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Regorafenib guide

Indications

Hepatocellular Carcinoma Regorafenib is a kinase inhibitor that is indicated: For the treatment of metastatic colorectal cancer (CRC) after disease progression on or intolerance to fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy. For the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) after disease progression on or intolerance to prior treatment with imatinib and sunitinib. ... Read moreRegorafenib is a kinase inhibitor that is indicated: For the treatment of metastatic colorectal cancer (CRC) after disease progression on or intolerance to fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy. For the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) after disease progression on or intolerance to prior treatment with imatinib and sunitinib. For the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib

Dosage and administration

Metastatic colorectal cancer (CRC): 160 mg orally, once daily for the first 21 days of each 28-day cycle.Gastrointestinal stromal tumours (GIST): 160 mg orally, once daily for the first 21 days of each 28-day cycle.Hepatocellular carcinoma (HCC): 160 mg orally, once daily for the first 21 days of each 28-day cycle.

Side effects

The most common side effects (≥30%) are asthenia/fatigue, decreased appetite and food intake, hand-foot skin reaction (HFSR) [palmar-plantar erythrodysesthesia (PPE)], diarrhea, mucositis, weight loss, infection, hypertension, and dysphonia.

Precautions and warnings

Hemorrhage: Permanently discontinue regorafenib for severe or life-threatening hemorrhage. Dermatological toxicity: Interrupt and then reduce or discontinue regorafenib depending on severity and persistence of dermatologic toxicity. Hypertension: Temporarily or permanently discontinue regorafenib for severe or uncontrolled hypertension. Cardiac ischemia and infarction: Withhold regorafenib for new or acute cardiac ischemia/infarction and resume only after resolution of acute ischemic events. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue regorafenib. Gastrointestinal perforation or fistulae: Discontinue regorafenib. Wound healing complications: Stop regorafenib before surgery. Discontinue in patients with wound dehiscence. Embryofetal toxicity: Can cause fetal harm. Advise women of potential risk to a fetus.

Pregnancy and lactation

Regorafenib is Pregnancy Category D. Based on its mechanism of action, Regorafenib can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies with Regorafenib in pregnant women. Based on animal reproduction studies Regorafenib was seen to cause embryo lethal and teratogenic defects and also increased the incidences of cardiovascular, genitourinary, and skeletal malformations in animals. Advice pregnant women or women with reproductive potential of the potential hazards of Regorafenib to the fetus. There is no information regarding the presence of regorafenib or its metabolites being excreted in human milk. Regorafenib and its metabolites were excreted in rat milk and because of the potential for serious adverse reactions in nursing infants from Regorafenib, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250